Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

InnoCare's Orelabrutinib Combination Shows 89.5% Response Rate in Phase 2 Marginal Zone Lymphoma Trial

By Public Technologies
  • InnoCare Pharma presented results from three orelabrutinib studies at the European Society for Medical Oncology Congress 2026.
  • A Phase 2 trial combining orelabrutinib with zuberitamab showed durable responses in previously untreated marginal zone lymphoma, with manageable safety.
  • Another Phase 2 study showed sustained benefit in relapsed or refractory chronic lymphocytic leukemia, with favorable long-term safety.
  • A retrospective study found orelabrutinib with rituximab deepened responses during maintenance treatment for intermediate- or high-risk marginal zone lymphoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610272030PRIMZONEFULLFEED9854775) on October 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.